1. Acosta, E.P., Henry, K., Weller, D., Page, L.M., Bacon, L., Rhame, F., Gilson, I., Rosenstein, H., Schacker, T., Fletcher, C.V., 1997. Indinavir pharmacokinetics and relationship between exposure and antiviral effect. 37th ICAAC, Abstract A-15, Toronto, Canada.
2. Positive effects of combined antiretroviral therapy on CD+ T cell homeostasis and function in advanced HIV disease;Autran;Science,1998
3. Bacheler, L.T., Rodgers, J.D., Lam, P.Y.S., Wright, M., Garber, S., Reid, C., Erickson-Viitanen, S., 1997. New cyclic urea-based protease inhibitors with improved potency, oral bioavailability and resistance profiles. Abstract-2, Sixth International Workshop on HIV drug resistance, treatment strategies and eradication, St. Petersburg, Florida.
4. Borin, M.T., Wang, Y., Schneck, D.W., Li, H., Brewer, J.E., Daenzer, C.L., 1998. Multi-dose safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections. Abstract 648, IL.
5. Buss, N. on be half of the fortovase study group, 1998. Saquinavir soft gel capsule (Fortovase™): pharmacokinetics and drug interactions. 5th conference on retroviruses and opportunistic infections. Abstract 354, IL.